COVID-19: La visión del residente de reumatología

espanolLa infeccion por SARS-CoV-2 se ha extendido por todo el mundo desde diciembre de 2019, en Wuhan, China. La pandemia ha demostrado ampliamente la resistencia de los sistemas de salud mundiales, convirtiendose en la mayor emergencia sanitaria desde la Segunda Guerra Mundial. No existe un enfoque terapeutico unico para el tratamiento de COVID-19 y el trastorno inmunitario asociado. La falta de ensayos clinicos aleatorizados (ECA) ha llevado a diferentes paises a enfrentar la enfermedad con base en series de casos, o a partir de resultados de estudios observacionales con farmacos fuera de ficha tecnica. Los reumatologos en general, y especificamente los residentes, hemos vivido en primera linea la pandemia, modificando nuestras actividades y alterando nuestro itinerario formativo. Hemos atendido pacientes, hemos aprendido el manejo y gracias a nuestra experiencia previa en farmacos para la artritis o la arteritis de celulas gigantes, hemos utilizado estos farmacos para tratar la COVID-19. EnglishSARS-CoV-2 infection has spread worldwide since it originated in December 2019, in Wuhan, China. The pandemic has largely demonstrated the resilience of the world's health systems and is the greatest health emergency since World War II. There is no single therapeutic approach to the treatment of COVID-19 and the associated immune disorder. The lack of randomised clinical trials (RCTs) has led different countries to tackle the disease based on case series, or from results of observational studies with off-label drugs. We as rheumatologists in general, and specifically rheumatology fellows, have been on the front line of the pandemic, modifying our activities and altering our training itinerary. We have attended patients, we have learned about the management of the disease and from our previous experience with drugs for arthritis and giant cell arteritis, we have used these drugs to treat COVID-19.